Systemic Lupus Erythematosus Epidemiology Forecast Insight

DelveInsight’s ‘Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast– 2030’ report delivers an in-depth understanding of the SLE, historical and forecasted epidemiology as well as the SLE market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Systemic Lupus Erythematosus Disease Understanding

Systemic Lupus Erythematosus Overview

According to the American College of Rheumatology “Systemic Lupus Erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Many patients experience fatigue, weight loss, and fever. Lupus flares vary from mild to serious. Most patients have times when the disease is active, followed by times when the disease is mostly quiet - referred to as a remission. Yet, there is much reason for hope.”


The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Lupus nephritis is a common and potentially disturbing sign of lupus. It is a leading cause of morbidity and mortality in patients with SLE. It leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney.


SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans. The disease is prone to relapses and remissions, resulting in considerable morbidity due to flares of disease activity and accumulated organ damage, and an increased risk of premature death, mostly due to infection or cardiovascular disease. SLE initially appears with symptoms such as drowsiness, illness, loss of appetite, and fever. Most of the affected patients also suffer from joint pain which typically affects the same joint on both sides of the body, weakness and muscle pain. The signs and symptoms of SLE vary among affected individuals and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system.


Also, some of the novel observations have provided an improved understanding of the contribution of tissue-specific factors and associated damage, T and B lymphocytes, as well as innate immune cell subsets and their corresponding abnormalities. SLE associated with intense polyclonal B-cell activation, with a population shift towards immature B cells. Memory B cells with increased CD27+/IgD are less disposed to immunosuppression. CD27-/IgD- memory B cells are related to increased disease activity and renal lupus. T cells that lead to the regulation of B-cell responses and helps in the infiltration of target tissues help to reduce the defects in signaling, adhesion, co-stimulation, gene transcription, and alternative splicing. The cytokines B-lymphocyte stimulator (BLys), interleukin 6, interleukin 17, interleukin 18, type I interferons, and tumor necrosis factor α (TNFα) are involved in the inflammatory process and are potential therapeutic targets.

Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of SLE, Age-specific Prevalent Population of SLE, Gender-specific Prevalent Population of SLE, and Severity-specific Prevalent Population of SLE in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.


Key Findings

This section provides glimpse of the SLE epidemiology in the 7MM.

  • The total diagnosed prevalent population of Systemic Lupus Erythematosus (SLE) in the 7MM ranges from 651,965 in 2020
  • Epidemiology assessed for SLE showed that the US, in 2020, accounted for approximately 351,176 prevalent cases of SLE.
  • In the United States, in 2020, there were 240, 1,070, 3,654, 7,283 and 8,181 cases, in the age groups 0–49 years, 50–59 years, 60–69 years, 70–79 years, and 80+ years, respectively.
  • In the United States, in 2020, the highest proportion of age-specific cases were observed in 40-59 years, followed by age groups of 19-39 years and 60+ years.
  • As per the analysis, a higher percentage of mild SLE was observed in the 7MM, followed by moderate SLE and severe SLE in 2020. In the US, moderate SLE accounted for the highest cases in 2020, followed by mild SLE with 161,541 and 112,376 cases, respectively. Whereas the lowest cases were observed in severe SLE, with 77,259 cases, in 2020.
  • Among the gender-specific prevalent contribution, females are affected more with SLE than male. In 2020, there were 34,837 prevalent cases of SLE in males and 316,339 prevalent cases in females in the US.
  • Among the EU-5 countries in 2020, the UK had the highest diagnosed prevalent population of SLE patients with 68,702 cases, followed by Germany (46,634) and Italy (42,767). In contrast, Spain had the lowest cases (35,662) in 2020.
  • As per the estimates, Japan accounted for 68,443 prevalent SLE cases in 2020.

Country Wise- Systemic Lupus Erythematosus Epidemiology

The epidemiology segment also provides the Systemic Lupus Erythematosus epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Scope of the Report

  • The report covers the descriptive overview of Systemic Lupus Erythematosus, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Systemic Lupus Erythematosus.

Report Highlight

  • Ten Year Forecast of Systemic Lupus Erythematosus
  • 7MM Coverage
  • Delvelnsight has analysed prevalent population of Systemic Lupus Erythematosus in the 7MM which suggests that the patient pool will increase during the forecast period of 2021–2030.
  • Age-specific data of SLE suggests that prevalence of SLE in the US, was highest in the age group of 40-59 years, followed by age groups of 19-39 years and 60+ years.
  • The scope of the report also encompasses another major segment, i.e., severity-specific prevalence of SLE, wherein higher percentage of mild SLE was observed in the 7MM, followed by moderate SLE and severe SLE in 2020. In the US, moderate SLE accounted for the highest cases in 2020, followed by mild SLE. Whereas the lowest cases were found in severe SLE in 2020.
  • Among the gender-specific prevalent contribution, females are affected more with SLE than male.

Analyst Comments

  • United States has shown an increasing trend toward SLE for past years, observable in the reported studies. SLE is more prevalent in women than men across all age groups and populations; the female-to-male ratio is highest at reproductive age.
  • Among EU5 countries, the United Kingdom has the highest prevalent population of SLE. Patients with late-onset SLE (≥ 50 years) tend to have a more insidious onset of disease with severe manifestations being infrequent.
  • SLE is a prototypic systemic autoimmune disease characterized by a broad spectrum of clinical manifestations and diverse immunological disorders. Japan has also shown the increasing trend of SLE like the US and EU5. Every year new cases are added, which correspond to a new rate of incidence and prevalence.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Systemic Lupus Erythematosus?
  • What is the historical Systemic Lupus Erythematosus patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Systemic Lupus Erythematosus in the 7MM?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Systemic Lupus Erythematosus?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Systemic Lupus Erythematosus during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Systemic Lupus Erythematosus report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Systemic Lupus Erythematosus market.
  • Quantify patient share distribution in the 7MM for Systemic Lupus Erythematosus.
  • The Systemic Lupus Erythematosus epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Systemic Lupus Erythematosus epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the Ten-year forecast period using reputable sources.

1. Key Insights

2. Report Introduction

3. Systemic Lupus Erythematosus (SLE) Market Overview at a Glance

4. Executive Summary of Systemic Lupus Erythematosus (SLE)

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Causes and Risk Factors

6.3. Symptoms

6.4. Clinical Manifestation

6.4.1. Constitutional

6.4.2. Dermatologic

6.4.3. Musculoskeletal

6.4.4. Pulmonary

6.4.5. Cardiac

6.4.6. Vascular

6.4.7. Renal

6.4.8. Gastrointestinal

6.4.9. Neuropsychiatric

6.5. Pathogenesis

6.5.1. Genetics of SLE

6.5.2. T-cell Signaling and Gene regulation in SLE

6.5.3. B-cell signaling in SLE

6.5.4. Role of Innate cells in SLE

6.6. Biologics and Biomarkers in the Treatment and Diagnosis of SLE

6.7. Diagnosis

6.8. Recent classification of SLE

7. EULAR Recommendations

8. The British Society for Rheumatology Guideline for the Management of Systemic Lupus Erythematosus in Adults (2017)

8.1. Recommendations for Clinical and Serological Features Prompting Consideration of a Diagnosis of Systemic Lupus Erythematosus (SLE)

8.2. Recommendations for the assessment of SLE patients

8.3. Recommendations for monitoring of SLE

8.4. Recommendations for the Management of Mild SLE

8.5. Recommendations for the Management of Moderate SLE

8.6. Recommendations for the Management of Severe SLE

9. European Evidence-based Recommendations for Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus: The SHARE Initiative (2017)

10. Clinical Practice Guidelines for Systemic Lupus Erythematosus: Recommendations for General Clinical Management (2016)

10.1. Recommendations and analysis of evidence

10.2. Recommendations for General Therapeutic Approach

10.2.1. Therapeutic purposes

10.2.2. Use of antimalarials

10.2.3. Use of glucocorticoids

10.2.4. Using nonbiological immunosuppressants

10.2.5. Use of biological treatments

10.2.6. Use of immunoglobulins

10.2.7. Indication of the therapeutic apheresis

10.2.8. Prevention of disease reactivation

10.2.9. Treatment of Systemic Lupus Erythematosus-associated asthenia

10.2.10. Photoprotection

11. Epidemiology and Patient Population

11.1. Key Findings

11.2. Epidemiology Methodology

11.3. Total Diagnosed Prevalent Population of SLE in the 7MM

11.4. Assumptions and Rationale

11.4.1. United States

11.4.2. EU5

11.4.2.1. Germany

11.4.2.2. France

11.4.2.3. Italy

11.4.2.4. Spain

11.4.2.5. United Kingdom

11.4.3. Japan

11.5. The United States

11.5.1. Total Diagnosed Prevalent Population of SLE in the United States

11.5.2. Age-specific Cases of Systemic Lupus Erythematosus (SLE) in the United States

11.5.3. Gender-specific Cases of Systemic Lupus Erythematosus (SLE) in the United States

11.5.4. Severity-specific Cases of SLE in the United States

11.6. EU5

11.6.1. Total Diagnosed Prevalent Population of SLE in EU5

11.6.2. Age-specific Cases of Systemic Lupus Erythematosus (SLE) in EU5

11.6.3. Gender-specific Cases of Systemic Lupus Erythematosus (SLE) in EU5

11.6.4. Severity-specific Cases of Systemic Lupus Erythematosus (SLE) in EU5

11.7. Japan

11.7.1. Total Diagnosed Prevalent Population of SLE in Japan

11.7.2. Age-specific Cases of Systemic Lupus Erythematosus (SLE) in Japan

11.7.3. Gender-specific Cases of Systemic Lupus Erythematosus (SLE) in Japan

11.7.4. Severity-specific Cases of Systemic Lupus Erythematosus (SLE) in Japan

12. Organizations contributing towards Systemic Lupus Erythematosus (SLE)

13. Patient Journey

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of Systemic lupus erythematosus (SLE) Market, and Epidemiology

Table 2: Key Events

Table 3: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)

Table 4: Summary of key pathogenic processes, cells, and molecules in SLE

Table 5: Differential Diagnosis of Systemic Lupus Erythematosus

Table 6: Diagnostic criteria for Systemic Lupus Erythematosus

Table 7: Classification criteria for Systemic Lupus Erythematosus

Table 8: 2019 EULAR Recommendations for the management of SLE

Table 9: Recommendations for cSLE – Diagnostic Procedures, Management, and treatment

Table 10: Recommendations for NP-cSLE – Diagnostic Procedures, and Treatment

Table 11: Total Diagnosed Prevalent Population of SLE in the 7MM (2018–2030)

Table 12: Total Diagnosed Prevalent Population of SLE in the US (2018–2030)

Table 13: Age-specific Cases of SLE in the United States (2018–2030)

Table 14: Gender-specific Cases of SLE in the US (2018–2030)

Table 15: Severity-specific Cases of SLE in the United States (2018–2030)

Table 16: Total Diagnosed Prevalent Population of SLE in EU5 (2018–2030)

Table 17: Age-specific Cases of SLE in EU5 (2018–2030)

Table 18: Gender-specific Cases of SLE in EU5 (2018–2030)

Table 19: Severity-specific Cases of SLE in EU5 (2018–2030)

Table 20: Total Diagnosed Prevalent Population of SLE in Japan (2018–2030)

Table 21: Age-specific Cases of SLE in Japan (2018–2030)

Table 22: Gender-specific Cases of SLE in Japan (2018–2030)

Table 23: Severity-specific Cases of SLE in Japan (2018–2030)

List of Figures

Figure 1: T-cell Signaling and Gene regulation in SLE

Figure 2: Role of Innate Cells (Neutrophils, Macrophages, and Dendritic Cells) in SLE

Figure 3: Algorithm for the diagnosis of Systemic Lupus Erythematosus

Figure 4: Total Diagnosed Prevalent Population of SLE in the 7MM (2018–2030)

Figure 5: Total Diagnosed Prevalent Population of SLE in the US (2018–2030)

Figure 6: Age-specific Cases of SLE in the United States (2018–2030)

Figure 7: Gender-specific Cases of SLE in the US (2018–2030)

Figure 8: Severity-specific Cases of SLE in the United States (2018–2030)

Figure 9: Total Diagnosed Prevalent Population of SLE in EU5 (2018–2030)

Figure 10: Age-specific Cases of SLE in EU5 (2018–2030)

Figure 11: Gender-specific Cases of SLE in EU5 (2018–2030)

Figure 12: Severity-specific Cases of SLE in EU5 (2018–2030)

Figure 13: Total Diagnosed Prevalent Population of SLE in Japan (2018–2030)

Figure 14: Age-specific Cases of SLE in Japan (2018–2030)

Figure 15: Gender-specific Cases of SLE in Japan (2018–2030)

Figure 16: Severity-specific Cases of SLE in Japan (2018–2030)

Forward to Friend

Need A Quote